Evolva & AnalytiCon enter Nuclear Receptor Alliance
Evolva Biotech SA and AnalytiCon Discovery GmbH announced that they have entered into a strategic alliance to jointly apply their respective technologies to the generation and optimization of novel nuclear receptor agonists and related compounds.
Under the terms of the agreement Evolva will be responsible for the creation and optimization of nuclear receptor agonists using its Watchmaker® technology, as well as pre-clinical development. AnalytiCon will provide selected genetic and compound diversity through its MEGAbolite®-process, and will be responsible for compound de-replication, identification and scale-up.
Neil Goldsmith, Managing Director of Evolva, said "Watchmaker® is bringing a new paradigm in drug discovery. By bridging nature's genetic diversity and chemistry with an evolution process it allows us to create small molecules optimized for specific therapeutic targets. Rather than to rely on nature to provide compounds of interest, we have designed a technology which evolves and delivers small molecules crafted for specific targets. We have already proven our approach can deliver novel, selective nuclear receptor agonists with desirable side-effect profiles. By securing a strategic collaboration with AnalytiCon, one of the leaders in modern natural product approaches, we recognize their expertise which complements judiciously our technology".
Weitere News aus dem Ressort Wirtschaft & Finanzen
